$LIVN

Bianchi Francesco sold $96K of LIVN

Bianchi Francesco sold 1,200 shares of LivaNova PLC (LIVN) at $80.19 on 2026-06-15.

Original reporting
SEC EDGAR · Bianchi Francesco
Published Jun 17, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LIVN
Bearish
medium confidence
Mentioned
$LIVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIVNBearishLow
01

Why it matters

The disclosure adds a fresh, timestamped data point on insider behavior, but the transaction’s dollar size is relatively small and does not indicate a corporate event (deal, guidance, enforcement).

02

Market read

Traders may briefly factor the insider sale into sentiment, but it is unlikely to drive a sustained repricing absent additional fundamental catalysts.

03

What to watch

The article does not state total insider holdings beyond post-transaction shares, nor whether other insiders/10b5-1 plans exist; those could contextualize the sale.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; transaction dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for LivaNova PLC.

Company-level read

Ticker impact

$LIVNBearishMedium confidence
Context

Director Bianchi Francesco filed an open-market sale of 1,200 LivaNova shares at $80.1900 on 2026-06-15, totaling $96,228.

Expected impact

Low-to-moderate downside bias for the stock around the filing date; magnitude likely limited given small dollar value and no 10b5-1 plan.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction size (~$96k) is modest and the absence of a pre-arranged 10b5-1 plan can add some sentiment sensitivity without implying a fundamental change.

Market effects

No sector-wide read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without follow-on buys, this may not reflect bearish fundamentals.

Key entities

  • LivaNova PLC

    Subject of the Form 4 insider transaction; director sold 1,200 shares.

  • Bianchi Francesco

    Director who executed the open-market sale.

Related articles

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

$LIVNHighAI 9/10

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev